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INTRODUCTION 
 In the present Evaluation, we have selected a Alogliptin (Anti diabetic drug) in 
which variety of pharmacological features are abundant. However, to dateanti-
inflammatory activities of this Drug have not beenreported. Its medicinal properties of 
dipeptidyl peptidase 4 inhibitors (DPP-4) reported by the researchers to opt for the 
assessment of anti-inflammatory activities in variousexperimental animal models. 
Dipeptidyl peptidase-4 (DPP-4) inhibitors are novel oralantihyperglycemic agents for 
treating type 2 diabetesmellitus patients. Recent studies suggest that several DPP-
4inhibitors exert suppressinginflammatory reactions. However, whether or not DPP-
4inhibitors suppress arterial inflammation and intimal hyperplasiaafter injury remains 
undetermined.Alogliptin(2-({6-[(3R)-3-aminopiperidinyl-1-yl]-3-methyl-2,4-dioxo-3,4-
dihydropyrimidin-1(2H)yl} methyl)benzonitrilemonobenzoate) (AGP) is a selective 
DPP-4 inhibitor that has improves glycemic control.However, it remains unknown 
whether AGP has anti-inflammatoryeffects. [1-7] 
DPP4 was first discovered by Hopsu-Havu and Glenner [8] in 1966. This protein is 
also called CD26 and is a ubiquitously expressed 110-kDa glycoprotein that belongs to 
the type 2 transmembrane protein family [9]. As a member of the serine peptidase/prolyl 
oligopeptidase family, DPP4 is often subclassified based on its structure and function as 
follows: membrane-bound peptidase (fibroblast activation protein (FAP)/seprase), 
resident cytoplasmic enzyme (DPP8 and DPP9), and nonenzymatic member (DPP6 and 
DPP10). These proteins share a typical α/β-hydrolase fold. DPP4 comprises four 
domains: a short cytoplasmic domain, a transmembrane domain, a flexible stalk segment, 
and the extracellular domain, which is further separated by a glycosylated region, the 
cysteine-rich region, and the catalytic region [10]. DPP4 can cleave dozens of peptides, 
including chemokines, neuropeptides, and regulatory peptides, containing a proline or 
alanine residue at position 2 of the amino-terminal region [11]. Despite the preference for 
proline at position 2, alternate residues at the penultimate position are also cleaved by 
DPP4, indicating a required stereochemistry for cleavage. This DPP4 cleavage at post-
proline peptide bonds inactivates peptides and/ or generates new bioactive peptides, 
thereby regulating diverse biological processes.  
DM is a low-grade systemic inflammatory disease. Suppressing inflammation slows 
the progression of DM. In addition to preserving glucose homeostasis, DPP4 inhibitors 
exert pleiotropic actions, such as anti-inflammatory effects. Alogliptin inhibits Toll-like 
receptor-4-mediated extracellular matrix signal-regulated kinase (ERK) activation and 
ERK-dependent matrix metalloproteinase expression in U937 histiocytes [12-13]. DPP4 
inhibitors reduce cyclooxygenase-2, IL-1β, macrophage inflammatory protein-2, and 
TLR-4-mediated IL-6 expression in Zucker Diabetic Fatty rat [14], diabetic 
apolipoprotein E-deficient mice [15], and C57BL/6J-obese/obese mice [16], which 
parallels recovery from disease. It is speculated that the anti-inflammatory properties of 
DPP4 inhibitors may be largely beneficial for DM. 
Alogliptin was first approved by the Pharmaceuticals and Medical Devices Agency 
of Japan in 2010 and by the FDA in 2013 for treating T2DM. It is a potent and highly 
selective inhibitor of DPP4 with a mean IC50 of 6.9 nM and 1,000-fold increased 
 selectivity for DPP4 compared with that of the closely related serine proteases DPP2, 
DPP8, DPP9, FAP/seprase, prolyl endopeptidase, and tryptase [17]. Alogliptin exhibits 
favorable pharmacokinetic, pharmacodynamic, and pharmacologic safety profiles. 
Therefore, alogliptin as a monotherapy or add-on to metformin, pioglitazone, glipizide, 
glibenclamide, voglibose, or insulin significantly improves glycemic control compared 
with placebo or active comparators in adult and elderly patients with inadequately 
controlled T2DM [18,19]. Because the kidney is the main excretion route for alogliptin, 
accounting for 60% to 71% [18] of excretion, the oral dose should be reduced or 
withdrawn in patients with renal impairment.  
Thus for its medicinal properties reported in the texts prompted us to select 
Evaluation of Alogliptinfor the Treatment of inflammation in different experimental 
animal models. 
MATERIALS AND METHODS 
Determination of anti-inflammatory activity:  
Carrageenan induced paw edema [20,21,22,23]: 
Group A: Toxicant control (0.1 ml of 1% w/v Carrageenan, hind paw) 
Group B: Standard (Ibuprofen 40 mg/ kg, p.o)
 
Group C: Alogliptin (1 mg/kg/day p.o) 
Group D: Alogliptin (2 mg/kg/day p.o) 
Group E: Alogliptin (3 mg/kg/day p.o) 
Experimental Procedure: 
5 groups ofWister albino rats of either sex weighing  180- 220 g, selected for the 
study were kept in colony cages at ambient temperature of 28±2°C and relative humidity 
of 45 to 55% with a 12:12 h light/dark cycle.The animals were fasted for 12 h before 
commencing the experiment with water ad libitum. The fasting was continued till 
completion of the experiment. Group A was served as normal toxicant control treated with 
toxicant carrageenan, group B with Ibuprofen (40 mg/kg p.o.) served as standard, groups 
C, D and E administered with Alogliptin(low, medium  and high doses p.o) respectively. 
The rats in Groups B, C, D and E were administered with 0.1 ml of 1% w/v of carrageenan 
into sub plantar region of right hind paw of rats 1 h after the administration of 
Ibuprofen/Alogliptin. Immediately thereafter the oedema volumes of the injected paws 
were measured plethysmographically at prefixed time intervals. 
2. Histamine induced paw edema[20,21,22,23]: 
Group A: Toxicant control (0.1 ml of 1% w/v histamine, hind paw) 
Group B: Standard (Ibuprofen 40 mg/ kg)
 
Group C: Alogliptin (1 mg/kg/day p.o) 
Group D: Alogliptin (2 mg/kg/day p.o) 
Group E: Alogliptin (3 mg/kg/day p.o) 
 Experimental Procedure: 
5 groups ofWister albino rats of either sex weighing  180- 220 g, selected for the 
study were kept in colony cages at ambient temperature of 28±2°C and relative humidity 
of 45 to 55% with a 12:12 h light/dark cycle.The animals were fasted for 12 h before 
commencing the experiment with water ad libitum. The fasting was continued till 
completion of the experiment. Group A was served as normal toxicant control treated with 
toxicant Histamine, group B with Ibuprofen (40 mg/kg p.o.) served as standard, groups C, 
D and E administered with Alogliptin(low, medium  and high doses p.o) respectively. The 
rats in Groups B, C, D and E were administered with 0.1 ml of 1% w/v of Histamine into 
sub plantar region of right hind paw of rats 1 h after the administration of 
Ibuprofen/Alogliptin. Immediately thereafter the oedema volumes of the injected paws 
were measured plethysmographically at prefixed time intervals. 
For comparison purpose, the volume of oedema was measured at prefixed time 
intervals. The difference between paw volumes of the treated animals was measured and 
the mean oedema volume was calculated. Percentage reduction in oedema volume was 
calculated by using the formula,                              
 Vo - Vt 
Percentage reduction  =      x 100 
   Vo 
 Where,   Vo = Volume of the paw of control at time‘t’.  
Vt = Volume of the paw of drug treated at time‘t’. 
 
Statistical analysis: 
All results will be expressed as mean ± SEM from 6 animals. Statistical difference in 
mean will be analyzed using one-way ANOVA (analysis of variance) followed by Post hoc 
test (Dunnett‘s‘t’ test). P< 0.05*, 0.01** and 0.001*** will be considered as statistically 
significant. 
 
 
 
 
 
 
RESULTS 
 1. Anti-inflammatory activity of Alogliptin in Carrageenan induced paw oedema 
model in rats: 
The Alogliptin with three selected doses i.e. 1, 2 and 3 mg/kg/day have exhibited 
a significant reduction in paw oedema volume in carrageenan induced paw oedema in 
rats at different time intervals. Results are tabulated in Table No. 1. Ibuprofen (40 mg/kg) 
was used as standard reference and it has significantly reduced paw oedema volume by 
32.97% at 1
st
 h, 57.48% at 2
nd
 h, 70.94% at 3
rd
 h and 82.03% at 4
th
 h, thus standard drug 
has exhibited time dependent reduction in oedema volume. 
During 1
st
 h of study Alogliptin with low, medium and high doses have 
significantly reduced oedema volume by 14.05%, 26.75%, 45.67% respectively, which 
was found to be a time dependent effect. 
During 2
nd
 h of study Alogliptin with low, medium and high doses have 
significantly reduced oedema volume by 26.68%, 38.17%, 53.14% respectively a time 
dependent effect. 
During 3
rd
 h of study Alogliptin with low, medium and high doses have 
significantly reduced oedema volume by 28.42%, 42.10%, 60.84% respectively a time 
dependent effect was noted. 
During 4
th
 h of study Alogliptin with low, medium and high doses have 
significantly reduced oedema volume by 36.92%, 51.49%, 65.46% respectively a time 
dependent effect was noted and result are graphically represented in Fig No.1. 
2. Anti-inflammatory activity of Alogliptin in Histamine induced paw oedema model 
in rats: 
The Alogliptin with three selected doses i.e. 1, 2 and 3 mg/kg have exhibited a 
significant reduction in paw oedema volume in histamine induced paw oedema in rats at 
different time intervals. Results are tabulated in Table No. 2. Ibuprofen (40 mg/kg) was 
used as standard reference and it has significantly reduced paw oedema volume by 
58.73% at 1
st
 h, 70.90% at 2
nd
 h, 84.72% at 3
rd
 h and 91.22% at 4
th
 h, thus exhibited a 
time dependent reduction in oedema volume. 
During 1
st
 h of study Alogliptin with low, medium and high doses have 
significantly reduced oedema volume by 9.25%, 20.63%, 39.68% respectively, which 
was found to be a time dependent effect. 
During 2
nd
 h of study Alogliptin with low, medium and high doses have 
significantly reduced oedema volume by 14.77%, 26.59%, 45.90% respectively noted a 
time dependent effect. 
During 3
rd
 h of study Alogliptin with low, medium and high doses have 
significantly reduced oedema volume by 19.95%, 34.62%, 54.58% respectively a time 
dependent effect was noted. 
During 4
th
 h of study Alogliptin with low, medium and high doses have 
significantly reduced oedema volume by 27.41%, 48.24%, 69.07% respectively a time 
dependent effect was noted and result are graphically represented in Fig No.2. 
  
 
DISCUSSION 
The present study is the first providing evidence that DPP-IV inhibitionwith Alogliptin 
has protective effects of diabeticanimals by a mechanism independent of enhanced 
insulin secretion. In the system of medicine a very good numbers of anti diabetic’s 
medicine are reported to produce anti-inflammatory activities. Hence in the present study 
a plant by name Alogliptinhas considered to evaluate its anti-inflammatory activities 
scientifically. For this Alogliptin were tested against different inflammatory models in 
rats.   
Carrageenan induced paw oedema model is used for screening of NSAIDs and 
inflammation produced by its biphasic in nature with the release of serotonin, bradykinin 
and histamine at I Phase followed by release of prostaglandins in II Phase which is shown 
in Table No.1 and Fig. No.1. 
Histamine being an important mediator of inflammation and also a potent 
vasodilator that causes increase in vascular permeability. In both phases due to release of 
these mediators cause pain and fever and Alogliptin significantly reduced paw oedema in 
II Phase of the inflammation indicating there effect on prostaglandins which is shown in 
Table No.2 and Fig. No.2. 
The present study evaluation of Anti diabetic drug Alogliptinconfirms a positive 
anti inflammatory effect, hence these might have contributed for the anti-inflammatory 
activity. 
CONCLUSION 
The results of recent studies suggest that dipeptidyl-peptidase-4 inhibitors (Alogliptin) 
have anti inflammatory effect on experimental models in rats. 
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Table No: 1. Anti-inflammatory effects of Alogliptin in Carrageenan induced paw oedema model in rats at different 
time intervals 
 
 
n = 6, Significant at P < 0.05*, 0.01** and 0.001***, ns = not significant. ROV- Reduction of Oedema Volume. 
 
 
 
S.No. Groups Treatment 1 h 
% 
ROV 
2 h % ROV 3 h % ROV 4 h % ROV 
A Toxicant 
Carrageenan 
(1% w/v) 
0.370 
±0.018 
-- 
0.461 
±0.017 
-- 
0.475 
±0.020 
-- 
0.501 
±0.017 
-- 
B Standard 
Ibuprofen 
40 mg/kg 
0.248 
±0.025
***
 
32.97 
 
0.196 
±0.024
***
 
57.48 0.138 
±0.008
***
 
70.94 0.090 
±0.017
***
 
82.03 
C Alogliptin 1 mg/kg 
0.318 
±0.020
ns
 
14.05 
0.338 
±0.027
ns
 
26.68 
0.340 
±0.017
*
 
28.42 
0.316 
±0.015
**
 
36.92 
D Alogliptin 2 mg/kg 
0.271 
±0.021
ns
 
26.75 
 
0.285 
±0.024
**
 
38.17 0.275 
±0.013
***
 
42.10 0.243 
±0.014
***
 
51.49 
E Alogliptin 3 mg/kg 0.201 
±0.013
*
 
45.67 
 
0.216 
±0.010
***
 
53.14 0.186 
±0.016
***
 
60.84 0.173 
±0.017
***
 
65.46 
 Table No: 2. Anti-inflammatory effects of Alogliptin in Histamine induced paw oedema model in rats at different time 
intervals 
 
 
 
n = 6, Significant at P < 0.05*, 0.01** and 0.001***, ns = not significant. ROV- Reduction of Oedema Volume. 
 
S.No. Groups Treatment 1 h % ROV 2 h 
% 
ROV 
3 h % ROV 4 h 
% 
ROV 
A Toxicant 
Histamine  
(1% w/v) 
0.378 
±0.011 
-- 
0.440 
±0.019 
-- 
0.491 
±0.008 
-- 
0.456 
±0.015 
-- 
B Standard 
Ibuprofen 
40 mg/kg 
0.156 
±0.015
***
 
58.73 0.128 
±0.013
***
 
70.90 0.075 
±0.021
***
 
84.72 0.040 
±0.019
***
 
91.22 
C Alogliptin 1 mg/kg 0.343 
±0.024
ns
 
9.25 0.375 
±0.023
ns
 
14.77 0.393 
±0.010
**
 
19.95 0.331 
±0.015
***
 
27.41 
D Alogliptin 2 mg/kg 0.300 
±0.018
*
 
20.63 0.323 
±0.029
***
 
26.59 0.321 
±0.010
***
 
34.62 0.236 
±0.015
***
 
48.24 
E Alogliptin 3 mg/kg 0.228 
±0.016
***
 
39.68 0.238 
±0.015
***
 
45.90 0.223 
±0.010
***
 
54.58 0.141 
±0.015
***
 
69.07 
 Fig No. 1 
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